Literature DB >> 9531248

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

J Jeppesen1, H O Hein, P Suadicani, F Gyntelberg.   

Abstract

BACKGROUND: The role of triglycerides as a risk factor of ischemic heart disease (IHD) remains controversial. For the present study, we examined the relation between fasting triglycerides and risk of IHD in the Copenhagen Male Study. METHODS AND
RESULTS: Baseline measurements of fasting lipids and other IHD risk factors were obtained for 2906 white men (age range, 53 to 74 years) who were initially free of overt cardiovascular disease. During an 8-year follow-up period, 229 men had a first IHD event. Crude cumulative incidence rates of IHD were 4.6% for the lowest, 7.7% for the middle, and 11.5% for the highest third of triglyceride levels (P for trend <.001). Compared with the lowest third level and adjusted for age, body mass index, alcohol, smoking, physical activity, hypertension, non-insulin-dependent diabetes mellitus, social class, and LDL and HDL cholesterol, relative risks of IHD (95% confidence interval) were 1.5 (1.0 to 2.3; P=.05) and 2.2 (1.4 to 3.4; P<.001) for the middle and highest third of triglyceride levels, respectively. When triglyceride levels were stratified by HDL cholesterol levels (triglyceride third multiplied by HDL cholesterol third), a clear gradient of risk of IHD was found with increasing triglyceride levels within each level of HDL cholesterol, including high HDL cholesterol level, which are thought to provide protection against IHD.
CONCLUSIONS: In middle-aged and elderly white men, a high level of fasting triglycerides is a strong risk factor of IHD independent of other major risk factors, including HDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531248     DOI: 10.1161/01.cir.97.11.1029

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  104 in total

1.  Lewis phenotypes, leisure time physical activity, and risk of ischaemic heart disease: an 11 year follow up in the Copenhagen male study.

Authors:  H O Hein; P Suadicani; F Gyntelberg
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

2.  Triglyceride as a risk factor, epidemiology.

Authors:  M Miller
Journal:  Lipids       Date:  1999       Impact factor: 1.880

Review 3.  Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care.

Authors:  Bruce J Holub
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

Review 4.  Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease.

Authors:  H N Ginsberg
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 2.931

Review 5.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 6.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 7.  Cardiovascular consequences of obese and nonobese obstructive sleep apnea.

Authors:  Kannan Ramar; Sean M Caples
Journal:  Med Clin North Am       Date:  2010-05       Impact factor: 5.456

Review 8.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  The role of triglycerides in cardiovascular risk.

Authors:  Puneet Gandotra; Michael Miller
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

10.  Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.

Authors:  Jonathan Isaacsohn; Donald Hunninghake; Helmut Schrott; Carlos A Dujovne; Robert Knopp; Stuart R Weiss; Harold Bays; John R Crouse; Michael H Davidson; Leonard M Keilson; James McKenney; Stanley G Korenman; Adrian S Dobs; Evan Stein; Ronald M Krauss; Darbie Maccubbin; Meehyung Cho; Diane J Plotkin; Yale B Mitchel
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.